Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

被引：29

作者：

Chiang, Chen-Yi ^{[1
]}

Hsieh, Chun-Hsiang ^{[1
]}

Chen, Mei-Yu ^{[1
]}

Tsai, Jy-Ping ^{[1
]}

Liu, Hsueh-Hung ^{[1
]}

Liu, Shih-Jen ^{[1
,2
]}

Chong, Pele ^{[1
,2
]}

Leng, Chih-Hsiang ^{[1
,2
]}

Chen, Hsin-Wei ^{[1
,2
]}

机构：

[1] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Zhunan 350, Miaoli, Taiwan

[2] China Med Univ, Grad Inst Immunol, Taichung, Taiwan

来源：

VACCINE | 2014年 / 32卷 / 12期

关键词：

Dengue virus; Envelope protein domain III; Lipoprotein; Vaccine; NONHUMAN-PRIMATES; NEUTRALIZING ANTIBODIES; FUSION PROTEIN; VIRUS; VACCINE; MICE; IMMUNOGENICITY; RESPONSES; CELLS; GLYCOPROTEIN;

D O I：

10.1016/j.vaccine.2014.01.041

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The combination of recombinant protein antigens with an immunostimulator has the potential to greatly increase the immunogenicity of recombinant protein antigens. In the present study, we selected the dengue-4 envelope protein domain III as a dengue vaccine candidate and expressed the protein in lipidated form using an Escherichia coli-based system. The recombinant lipidated dengue-4 envelope protein domain III folded into the proper conformation and competed with the dengue-4 virus for cellular binding sites. Mice immunized with lipidated dengue-4 envelope protein domain III without exogenous adjuvant had higher frequencies of dengue-4 envelope protein domain III-specific B cells secreting antibodies than mice immunized with the nonlipidated form. Importantly, lipidated dengue-4 envelope protein domain III-immunized mice demonstrated a durable neutralizing antibody response and had reduced viremia levels after challenge. The study demonstrates that lipidated dengue-4 envelope protein domain III is immunogenic and may be a potential dengue vaccine candidate. Furthermore, the lipidation strategy can be applied to other serotypes of dengue virus. (C) 2014 The Authors. Published by Elsevier Ltd. All rights reserved.

引用

页码：1346 / 1353

页数：8

共 40 条

[1] Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice [J].

Babu, J. Pradeep ;

Pattnaik, Priyabrata ;

Gupta, Nimesh ;

Shrivastava, Ambuj ;

Khan, Mohsin ;

Rao, P. V. Lakshmana .

VACCINE, 2008, 26 (36) :4655-4663

[2] Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial [J].

Beckett, Charmagne G. ;

Tjaden, Jeffrey ;

Burgess, Timothy ;

Danko, Janine R. ;

Tamminga, Cindy ;

Simmons, Monika ;

Wu, Shuenn-Jue ;

Sun, Peifang ;

Kochel, Tadeusz ;

Raviprakash, Kanakatte ;

Hayes, Curtis G. ;

Porter, Kevin R. .

VACCINE, 2011, 29 (05) :960-968

[3] Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates [J].

Bernard, Lidice ;

Izquierdo, Alienys ;

Alvarez, Mayling ;

Rosario, Delfina ;

Prado, Irina ;

Lopez, Carlos ;

Martinez, Rafael ;

Castro, Jorge ;

Santana, Ernidalys ;

Hermida, Lisset ;

Guillen, Gerardo ;

Guzman, Maria G. .

ANTIVIRAL RESEARCH, 2008, 80 (02) :194-199

[4] The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice [J].

Bernardo, Lidice ;

Pavon, Alequis ;

Hermida, Lisset ;

Gil, Lazaro ;

Valdes, Iris ;

Cabezas, Sheila ;

Linares, Ramon ;

Alvarez, Mayling ;

Silva, Ricardo ;

Guillen, Gerardo ;

Nagy, Eszter ;

Schlick, Petra ;

Guzman, Maria G. .

VACCINE, 2011, 29 (25) :4256-4263

[5] The global distribution and burden of dengue [J].

Bhatt, Samir ;

Gething, Peter W. ;

Brady, Oliver J. ;

Messina, Jane P. ;

Farlow, Andrew W. ;

Moyes, Catherine L. ;

Drake, John M. ;

Brownstein, John S. ;

Hoen, Anne G. ;

Sankoh, Osman ;

Myers, Monica F. ;

George, Dylan B. ;

Jaenisch, Thomas ;

Wint, G. R. William ;

Simmons, Cameron P. ;

Scott, Thomas W. ;

Farrar, Jeremy J. ;

Hay, Simon I. .

NATURE, 2013, 496 (7446) :504-507

[6] A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice [J].

Block, Olivia K. T. ;

Rodrigo, W. W. Shanaka I. ;

Quinn, Matthew ;

Jin, Xia ;

Rose, Robert C. ;

Schlesinger, Jacob J. .

VACCINE, 2010, 28 (51) :8085-8094

[7] Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus [J].

Brady, Oliver J. ;

Gething, Peter W. ;

Bhatt, Samir ;

Messina, Jane P. ;

Brownstein, John S. ;

Hoen, Anne G. ;

Moyes, Catherine L. ;

Farlow, Andrew W. ;

Scott, Thomas W. ;

Hay, Simon I. .

PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (08)

[8] A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates [J].

Chen, Hsin-Wei ;

Liu, Shih-Jen ;

Li, Yi-Shiuan ;

Liu, Hsueh-Hung ;

Tsai, Jy-Ping ;

Chiang, Chen-Yi ;

Chen, Mei-Yu ;

Hwang, Chyi-Sing ;

Huang, Chin-Cheng ;

Hu, Hui-Mei ;

Chung, Han-Hsuan ;

Wu, Sze-Hsien ;

Chong, Pele ;

Leng, Chih-Hsiang ;

Pan, Chien-Hsiung .

ARCHIVES OF VIROLOGY, 2013, 158 (07) :1523-1531

[9] A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design [J].

Chen, Hsin-Wei ;

Liu, Shih-Jen ;

Liu, Hsueh-Hung ;

Kwok, Yan ;

Lin, Chang-Ling ;

Lin, Li-Hsiu ;

Chen, Mei-Yu ;

Tsai, Jy-Ping ;

Chang, Li-Sheng ;

Chiu, Fang-Feng ;

Lai, Li-wei ;

Lian, Wei-Cheng ;

Yang, Chiou-Ying ;

Hsieh, Shih-Yang ;

Chong, Pele ;

Leng, Chih-Hsiang .

VACCINE, 2009, 27 (09) :1400-1409

[10] Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate [J].

Chen, YP ;

Maguire, T ;

Hileman, RE ;

Fromm, JR ;

Esko, JD ;

Linhardt, RJ ;

Marks, RM .

NATURE MEDICINE, 1997, 3 (08) :866-871

← 1 2 3 4 →